Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENVB Enveric Biosciences

Not Yet Opened 12-18 16:00:00 EST

5.06

-0.47

-8.59%

盘后5.18

+0.12+2.41%

19:45 EST

High5.68	Low4.98	Vol93.21K
Open5.61	D1 Closing5.53	Amplitude12.75%
Mkt Cap3.02M	Tradable Cap3.00M	Total Shares597.00K
T/O490.85K	T/O Rate15.68%	Tradable Shares594.40K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENVB","market":"US","secType":"STK","nameCN":"Enveric Biosciences","latestPrice":5.055,"timestamp":1766091600000,"preClose":5.53,"halted":0,"volume":93206,"hourTrading":{"tag":"盘后","latestPrice":5.1768,"preClose":5.055,"latestTime":"19:45 EST","volume":1418,"amount":7151.3689,"timestamp":1766105116934},"delay":0,"floatShares":594400,"shares":597000,"eps":-126.04987,"marketStatus":"Not Yet Opened","change":-0.475,"latestTime":"12-18 16:00:00 EST","open":5.61,"high":5.68,"low":4.975,"amount":490849.639328,"amplitude":0.127486,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-126.04987,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":5.53,"preHourTrading":{"tag":"盘前","latestPrice":5.45,"preClose":5.53,"latestTime":"09:24 EST","volume":2426,"amount":13325.161622,"timestamp":1766067864978},"postHourTrading":{"tag":"盘后","latestPrice":5.1768,"preClose":5.055,"latestTime":"19:45 EST","volume":1418,"amount":7151.3689,"timestamp":1766105116934},"volumeRatio":0.202403,"impliedVol":6.7116,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ENVB/tweets","defaultTab":"tweets","newsList":[{"id":"2590545572","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 01:43 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2590545572","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590545572?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:43","pubTimestamp":1765478607,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 01:43 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nAQN2LD9IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2590454557","title":"Enveric Biosciences Raises $3.1 Million Through Warrant Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2590454557","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590454557?lang=en_us&edition=fundamental","pubTime":"2025-12-12 02:43","pubTimestamp":1765478598,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. has announced the immediate exercise of certain outstanding warrants, resulting in approximately $3.1 million in gross proceeds. The company entered into definitive agreements to allow for the exercise of warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, down from previous exercise prices of $36.00 and $10.98. In connection with the exercise, Enveric will also issue new unregistered Series E and Series F warrants, each allowing purchases of up to 426,390 shares at $7.05 per share. The Series E warrants will expire five years after the effective date of the resale registration statement, while the Series F warrants will expire eighteen months after that date. The proceeds will be used for product development, working capital, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL9J0WzF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2590543300","title":"Enveric Biosciences Enacts 1-for-12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2590543300","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590543300?lang=en_us&edition=fundamental","pubTime":"2025-12-12 01:41","pubTimestamp":1765474896,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. implemented a 1-for-12 reverse stock split on October 23, 2025. The company's shares began trading on a split-adjusted basis on October 28, 2025, with every 12 shares of common stock reclassified as one share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL1xcY72:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2590317345","title":"Crude Oil Moves Lower; Photronics Shares Surge After Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2590317345","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590317345?lang=en_us&edition=fundamental","pubTime":"2025-12-11 01:19","pubTimestamp":1765387195,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/12/49312357/crude-oil-moves-lower-photronics-shares-surge-after-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","SQQQ","BK4603","BRZE","BK4147","QID","PLAB","NVIW.SI","PSQ","USAW.SI","BK4023","BK4175","BK4585","TQQQ","AVAV","TSYW.SI","ENVB","BK4007","BK4588","BK4187","NQmain","MAMA","BK4613","QLD",".IXIC","USJW.SI","BK4212"],"gpt_icon":1},{"id":"2590837211","title":"What Sparked Enveric Biosciences (ENVB) 74% Surge In After-Hours Trading?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590837211","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590837211?lang=en_us&edition=fundamental","pubTime":"2025-12-10 11:31","pubTimestamp":1765337460,"startTime":"0","endTime":"0","summary":"Enveric Biosciences shares soared 73.82% in after-hours trading after the company received a patent allowance for its EVM301 Series molecules.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Drug-Delivery-Ideas-Emerge.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Drug-Delivery-Ideas-Emerge.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49296195/what-sparked-enveric-biosciences-envb-74-surge-in-after-hours-trading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49296195/what-sparked-enveric-biosciences-envb-74-surge-in-after-hours-trading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2590349807","title":"Enveric Biosciences Receives USPTO Notice of Allowance for EVM301 Series Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2590349807","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590349807?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:01","pubTimestamp":1765285277,"startTime":"0","endTime":"0","summary":"Enveric Biosciences announced it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application related to its EVM301 Series of drug candidates. The patent application, titled \"N-heterocycle substituted tryptamine derivatives and methods of using,\" covers compositions and methods of use for potential neuroplastogenic non-hallucinogenic molecules aimed at treating neuropsychiatric and addiction disorders. The company highlighted that its lead asset, EB-003, is designed to selectively engage both 5-HTA and 5-HTB receptors to provide fast-acting and durable antidepressant and anxiolytic effects, while minimizing hallucinogenic side effects.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL1p7339:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB","BK4211","EXSR"],"gpt_icon":0},{"id":"2588888445","title":"Enveric Biosciences to Present at Sachs Neuroscience Innovation Forum and Biotech Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2588888445","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588888445?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:01","pubTimestamp":1764853278,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. will present and participate in a panel discussion at the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026, during \"J.P. Morgan Week 2026\" in San Francisco. The company will also attend the Biotech Showcase 2026, held from January 12-14, 2026, at the Hilton San Francisco Union Square. During these events, Enveric's management team will engage with investors and potential partners to highlight their business strategy, recent achievements, and upcoming milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire  on December 04, 2025, and is solely responsible for the information c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4q2zGb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2586625217","title":"Enveric Biosciences Receives Fourth Notice of Allowance for Evm401 Series of Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2586625217","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586625217?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:00","pubTimestamp":1764162052,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nFWN3X20I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2586252255","title":"Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2586252255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586252255?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:00","pubTimestamp":1764162036,"startTime":"0","endTime":"0","summary":"Enveric Biosciences announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application related to its EVM401 Series of molecules. This is the fourth patent application from Enveric for the EVM401 Series, which covers substituted ethylamine fused heterocyclic mescaline derivatives. The claims in the application are expected to expand the company's pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules aimed at treating neuropsychiatric and addiction disorders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire  on November 26, 2025, and is so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL43FHZy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2583682392","title":"Enveric Biosciences Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682392?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:36","pubTimestamp":1763156177,"startTime":"0","endTime":"0","summary":"Enveric Biosciences ( ($ENVB) ) has provided an announcement. On November 12, 2025, Enveric Biosciences, Inc. received a notification from the Nasd...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/enveric-biosciences-regains-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/enveric-biosciences-regains-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENVB","NQmain","NVIW.SI","BK4007","SQQQ","TQQQ","QID",".IXIC","USAW.SI","MNQmain","USJW.SI","TSYW.SI","PSQ","QLD"],"gpt_icon":0},{"id":"2583681093","title":"Enveric Biosciences Q3 EPS $(10.81) Up From $(43.10) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681093","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681093?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:09","pubTimestamp":1763154553,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Q3 EPS $(10.81) Up From $(43.10) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48880018/enveric-biosciences-q3-eps-10-81-up-from-43-10-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Enveric Biosciences Q3 EPS $(10.81) Up From $(43.10) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB"],"gpt_icon":0},{"id":"2583681760","title":"Enveric Biosciences posts Q3 net loss of $3.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681760","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681760?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154341,"startTime":"0","endTime":"0","summary":"Enveric Biosciences reported a net loss attributable to common stockholders of $3.4 million for the third quarter ended September 30, 2025, or $10.8 per share, compared to a net loss of $2.1 million, or $43.1 per share, for the same period in 2024, adjusted for the reverse stock split. The net loss included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. As of September 30, 2025, the company held $3.8 million in cash and cash equivalents and raised $7.9 million in net proceeds during the nine months ended September 30, 2025. Key business developments included progress towards clinical trials for lead candidate EB-003, completion of chemistry, manufacturing, and controls milestones, dose range studies, and efforts to expand and defend the company's intellectual property portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL374p54:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","BK4007","BK4211","EXSR"],"gpt_icon":0},{"id":"2583681788","title":"Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681788?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUABW6YKQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2578085196","title":"Enveric Biosciences trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2578085196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578085196?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:50","pubTimestamp":1761609010,"startTime":"0","endTime":"0","summary":"19:50 EDT Enveric Biosciences (ENVB) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-biosciences-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2577092223","title":"Enveric Biosciences Announces 1-for-12 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2577092223","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577092223?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:01","pubTimestamp":1761220910,"startTime":"0","endTime":"0","summary":"Enveric Biosciences Inc. will implement a 1-for-12 reverse stock split of its common stock, effective October 28, 2025. The move will reduce the number of shares outstanding from approximately 6.2 million to about 518,000. Enveric's shares will continue trading on the Nasdaq Capital Market under the symbol \"ENVB\" on a split-adjusted basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire  on October 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL9k2lCq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2577309280","title":"BRIEF-Enveric Biosciences Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2577309280","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577309280?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:01","pubTimestamp":1761220906,"startTime":"0","endTime":"0","summary":"BRIEF-Enveric Biosciences Announces Reverse Stock SplitOct 23 (Reuters) - Enveric Biosciences Inc ENVB.O:ENVERIC BIOSCIENCES ANNOUNCES REVERSE STOCK SPLITENVERIC BIOSCIENCES INC: TO EFFECT A REVERSE S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUA4Z9NHK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2575574617","title":"Enveric Biosciences Secures 23rd U.S. Patent for Novel Neuroplastogenic Compounds Targeting Mental Health Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2575574617","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575574617?lang=en_us&edition=fundamental","pubTime":"2025-10-16 20:30","pubTimestamp":1760617845,"startTime":"0","endTime":"0","summary":"Enveric Biosciences announced the issuance of its 23rd U.S. patent for novel compounds within its neuroplastogenic patent estate. The new patent, U.S. Patent No. 12,428,408, titled \"Fused Heterocyclic Mescaline Derivatives,\" covers a unique series of compounds designed to target key serotonin receptors and promote neuroplasticity. The company highlighted this milestone as part of its ongoing efforts to expand its intellectual property portfolio and advance next-generation molecules for potential treatment of neuropsychiatric conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire  on October 16, 2025, and is solely responsible ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL5vDcGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2575847347","title":"Enveric hires firm to contest post-grant review petition filed by Gilgamesh","url":"https://stock-news.laohu8.com/highlight/detail?id=2575847347","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575847347?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:16","pubTimestamp":1760530567,"startTime":"0","endTime":"0","summary":"Enveric Biosciences (ENVB) announced that it has hired Fish and Richardson P.C. to contest a post-grant review petition filed by Gilgamesh Pharmace...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/enveric-hires-firm-to-contest-post-grant-review-petition-filed-by-gilgamesh-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/enveric-hires-firm-to-contest-post-grant-review-petition-filed-by-gilgamesh-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ENVB","BK4007"],"gpt_icon":0},{"id":"2575128781","title":"Enveric Biosciences Hires Ip Powerhouse to Defend Its U.S. Patent With Claims Relevant to Bretisilocin, Recently Acquired by Abbvie in $1.2 Billion Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2575128781","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575128781?lang=en_us&edition=fundamental","pubTime":"2025-10-15 20:00","pubTimestamp":1760529603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nTUA8D9J5C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ENVB"],"gpt_icon":0},{"id":"2575213478","title":"Enveric Biosciences to Explore and Negotiate Potential Digital Asset Treasury Strategy Opportunities to Support Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2575213478","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575213478?lang=en_us&edition=fundamental","pubTime":"2025-10-14 21:00","pubTimestamp":1760446833,"startTime":"0","endTime":"0","summary":"Enveric Biosciences to Explore and Negotiate Potential Digital Asset Treasury Strategy Opportunities to Support Long-Term Growth. Enveric Biosciences Inc. announced that its Board of Directors has authorized the Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury  strategy opportunities. These opportunities will be subject to further review and approval by the full Board. The company stated that this initiative aims to enhance shareholder value and support long-term growth, while maintaining a focus on advancing its core biotechnology programs. Further updates will be provided as developments occur.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. publis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7BtkC6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ENVB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.enveric.com","stockEarnings":[{"period":"1week","weight":-0.0708},{"period":"1month","weight":-0.1085},{"period":"3month","weight":-0.2998},{"period":"6month","weight":-0.6683},{"period":"1year","weight":-0.9139},{"period":"ytd","weight":-0.9216}],"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.173361},{"month":2,"riseRate":0.375,"avgChangeRate":0.066295},{"month":3,"riseRate":0.25,"avgChangeRate":-0.163046},{"month":4,"riseRate":0.25,"avgChangeRate":-0.094772},{"month":5,"riseRate":0.25,"avgChangeRate":0.090831},{"month":6,"riseRate":0.75,"avgChangeRate":0.050985},{"month":7,"riseRate":0.375,"avgChangeRate":-0.077722},{"month":8,"riseRate":0.375,"avgChangeRate":-0.104625},{"month":9,"riseRate":0.375,"avgChangeRate":-0.104281},{"month":10,"riseRate":0.125,"avgChangeRate":-0.243904},{"month":11,"riseRate":0.375,"avgChangeRate":1.818773},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.125035}],"exchange":"NASDAQ","name":"Enveric Biosciences","nameEN":"Enveric Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Enveric Biosciences(ENVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Enveric Biosciences,ENVB,Enveric Biosciences股票,Enveric Biosciences股票老虎,Enveric Biosciences股票老虎国际,Enveric Biosciences行情,Enveric Biosciences股票行情,Enveric Biosciences股价,Enveric Biosciences股市,Enveric Biosciences股票价格,Enveric Biosciences股票交易,Enveric Biosciences股票购买,Enveric Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Enveric Biosciences(ENVB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Enveric Biosciences(ENVB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}